CRISPR Therapeutics AG (CRSP) Research & Development (2015 - 2026)
CRISPR Therapeutics AG (CRSP) reported Research & Development of $68.6 million for Q1 2026, down 5.39% on a YoY basis from $72.5 million in Q1 2025, and up 427.49% sequentially from $13.0 million in Q4 2025.
CRISPR Therapeutics AG (CRSP) Research & Development (2015 - 2026) Analysis & Trends
CRISPR Therapeutics AG (CRSP) has 12 years of Research & Development data on file, last reported at $68.6 million in Q1 2026.
- For the quarter ending Q1 2026, Research & Development fell 5.39% year-over-year to $68.6 million; the trailing twelve-month figure through Mar 2026 stood at $210.4 million (down 31.37% YoY), and the FY2025 full-year result was $284.8 million, down 8.2% from the prior year.
- Research & Development grew to $68.6 million in Q1 2026, from $13.0 million in the prior quarter.
- In the past five years, Research & Development ranged from a high of $123.2 million in Q2 2022 to a low of $13.0 million in Q4 2025.
- A 5-year average of $84.8 million and a median of $82.2 million in 2024 frame the typical range for Research & Development.
- Across the five-year window, Research & Development jumped 67.44% in 2022 and slumped 81.88% in 2025, its largest moves.
- Tracing CRSP's Research & Development over 5 years: stood at $103.6 million in 2022, then retreated by 8.12% to $95.1 million in 2023, then declined by 24.6% to $71.7 million in 2024, then tumbled by 81.88% to $13.0 million in 2025, then jumped by 427.49% to $68.6 million in 2026.
- Business Quant data shows CRSP's Research & Development at $68.6 million in Q1 2026, $13.0 million in Q4 2025, and $58.9 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | R&D (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | -17.94 Mn |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 541.22 Mn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | -2.31 Mn |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 961.60 Mn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 1.54 Bn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | 15.66 Mn |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | 1.37 Bn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | 343.97 Mn |
| 10 | CRISPR Therapeutics AG | 4.57 Bn | 2.12 Bn | - | 68.57 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 68.57 Mn |
| Dec 31, 2025 | 13.00 Mn |
| Sep 30, 2025 | 58.90 Mn |
| Jun 30, 2025 | 69.89 Mn |
| Mar 31, 2025 | 72.48 Mn |
| Dec 31, 2024 | 71.74 Mn |
| Sep 30, 2024 | 82.16 Mn |
| Jun 30, 2024 | 80.17 Mn |
| Mar 31, 2024 | 76.17 Mn |
| Dec 31, 2023 | 95.14 Mn |
| Sep 30, 2023 | 90.70 Mn |
| Jun 30, 2023 | 101.56 Mn |
| Mar 31, 2023 | 99.94 Mn |
| Dec 31, 2022 | 103.56 Mn |
| Sep 30, 2022 | 116.62 Mn |
| Jun 30, 2022 | 123.22 Mn |
| Mar 31, 2022 | 118.25 Mn |
| Dec 31, 2021 | 103.10 Mn |
| Sep 30, 2021 | 83.50 Mn |
| Jun 30, 2021 | 82.33 Mn |